74 related articles for article (PubMed ID: 28270736)
1. Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?
Bernardi D; Stefani M; Boccalon M; Raiti C
Curr Oncol; 2017 Feb; 24(1):e76-e77. PubMed ID: 28270736
[No Abstract] [Full Text] [Related]
2. Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission.
Haq R; Gulasingam P
Curr Oncol; 2016 Apr; 23(2):91-5. PubMed ID: 27122973
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.
Yeo B; Kotsori K; Mohammed K; Walsh G; Smith IE
Breast; 2015 Dec; 24(6):751-7. PubMed ID: 26456898
[TBL] [Abstract][Full Text] [Related]
4. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.
Witzel I; Müller V; Abenhardt W; Kaufmann M; Schoenegg W; Schneeweis A; Jänicke F
BMC Cancer; 2014 Nov; 14():806. PubMed ID: 25371387
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
6. How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?
Hacioglu B; Akin S; Babacan T; Sever AR; Altundag K
Future Oncol; 2015; 11(20):2799-801. PubMed ID: 26344497
[No Abstract] [Full Text] [Related]
7. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
[TBL] [Abstract][Full Text] [Related]
10. Autologous bone marrow transplantation for metastatic breast cancer.
Saez RA; Selby GB; Slease RB; Epstein RB; Mandanas RA; Confer DL
J Okla State Med Assoc; 1994 Sep; 87(9):405-10. PubMed ID: 7996314
[TBL] [Abstract][Full Text] [Related]
11. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
Dao BD; Ho H; Quintal LN
J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300
[TBL] [Abstract][Full Text] [Related]
12. Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases.
Artac M; Koral L; Toy H; Guler T; Boruban MC; Altundag K
J Oncol Pharm Pract; 2014 Apr; 20(2):141-5. PubMed ID: 23676508
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia--monitoring the effect of an expensive medicine access program.
Pearson SA; Ringland CL; Ward RL
J Clin Oncol; 2007 Aug; 25(24):3688-93. PubMed ID: 17704417
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.
Gennari R; Menard S; Fagnoni F; Ponchio L; Scelsi M; Tagliabue E; Castiglioni F; Villani L; Magalotti C; Gibelli N; Oliviero B; Ballardini B; Da Prada G; Zambelli A; Costa A
Clin Cancer Res; 2004 Sep; 10(17):5650-5. PubMed ID: 15355889
[TBL] [Abstract][Full Text] [Related]
15. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
16. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
Bishop AJ; Ensor J; Moulder SL; Shaitelman SF; Edson MA; Whitman GJ; Bishnoi S; Hoffman KE; Stauder MC; Valero V; Buchholz TA; Ueno NT; Babiera G; Woodward WA
Cancer; 2015 Dec; 121(24):4324-32. PubMed ID: 26348887
[TBL] [Abstract][Full Text] [Related]
17. First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study.
Aitelhaj M; Lkhoyaali S; Rais G; Boutayeb S; Errihani H
Pan Afr Med J; 2016; 24():324. PubMed ID: 28154679
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
[TBL] [Abstract][Full Text] [Related]
19. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
20. [A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel].
Ogino T; Komoike Y; Ishitobi M; Motomura K; Inaji H; Koyama H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2234-6. PubMed ID: 19106581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
